Genolution Inc is a Korea-based company principally engaged in the manufacture and distribution of molecular diagnostic equipment and products related to ribonucleic acid interference (RNAi) research. The Company is mainly engaged in the manufacture and sales of nucleic acid extraction reagents for extracting nucleic acids from human samples and automated nucleic acid extraction devices for automatically extracting nucleic acids from samples. The Company also provides RNAi services. The Company distributes its products within domestic market and to overseas markets.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-10-14	₩1,458.00	0.00%	17,875
26-10-13	₩1,458.00	-0.07%	30,927
26-10-12	₩1,459.00	+1.04%	39,880
26-10-08	₩1,444.00	+3.07%	48,306
26-10-07	₩1,401.00	-2.03%	62,685

End-of-day quote Korea S.E.

More quotes

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. 2026-10-14			5-day change	1st Jan Change
1,458.00 ^KRW	0.00%		+4.07%	-23.22%

02-18	Kim Ki-ok completed the acquisition of 4.22% stake in Genolution Inc. from HoilBioMed Co., Ltd.	CI
01-20	Kim Ki-ok agreed to acquire 4.22% stake in Genolution Inc. from HoilBioMed Co., Ltd for KRW 1.5 billion.	CI

Market Cap	26.34B 19.63M 17.65M 16.47M 14.92M 28.02M 1.87B 28.2M 198M 77.17M 969M 73.69M 72.09M 3.12B	P/E 2024	-5.89x	P/E 2025	-2.95x
Enterprise Value	22.46B 16.73M 15.04M 14.04M 12.72M 23.89M 1.59B 24.04M 168M 65.78M 826M 62.82M 61.46M 2.66B	EV / Sales 2024	4.38x	EV / Sales 2025	3.23x
Free-Float	66.52%	Yield 2024 *	-	Yield 2025	-

02-18	Kim Ki-ok completed the acquisition of 4.22% stake in Genolution Inc. from HoilBioMed Co., Ltd.	CI
01-20	Kim Ki-ok agreed to acquire 4.22% stake in Genolution Inc. from HoilBioMed Co., Ltd for KRW 1.5 billion.	CI
24-07-30	Genolution Inc. cancelled the transaction announced on May 7, 2024	CI
24-05-06	Genolution Inc. announced that it expects to receive CNY 750.00284 million in funding from RICO Asset Management Co., Ltd. and another investor	CI
24-01-09	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on July 10, 2023.	CI
24-01-09	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on July 10, 2023.	CI
24-01-08	Genolution Inc.'s Equity Buyback announced on July 10, 2023, has expired with 477,003 shares, representing 2.59% for KRW 1,989.17 million.	CI
23-10-13	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on July 10, 2023.	CI
23-07-10	Genolution Inc. announces an Equity Buyback for KRW 2,000 million worth of its shares.	CI
23-07-09	Genolution Inc. authorizes a Buyback Plan.	CI
23-05-15	Genolution Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
23-04-05	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on October 6, 2022.	CI
23-04-05	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on October 6, 2022.	CI

1 week	+4.07%
Current month	-1.35%
1 month	-1.42%
3 months	+7.36%
6 months	-24.46%
Current year	-23.22%

Genolution Inc. Stock

Stocks

A225220

KR7225220003

Biotechnology & Medical Research

Valuation: Genolution Inc.

Chart: Genolution Inc.

Latest news: Genolution Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Genolution Inc.

Latest insider transactions

Bio Diagnostics & Testing

Financials

Company Profile

Quotes

1 week	1,396	1,479
1 month	1,372	1,484
Current year	957	2,120
1 year	957	2,325
3 years	957	5,140
5 years	957	8,391.09
10 years	957	13,118.81

Manager	Title	Age	Since
Min-Ee Kim CEO	Chief Executive Officer	40	-
Ki-Ok Kim CEO	Chief Executive Officer	71	2006-01-31
Sang-Hoon Kim DFI	Director of Finance/CFO	66	-

Director	Title	Age	Since
Ki-Ok Kim BRD	Director/Board Member	71	2006-01-31
Hak-Soo Lee BRD	Director/Board Member	70	2020-03-19
Min-Ee Kim BRD	Director/Board Member	40	-

Date	Insider	Type	Main position	Quantity	% Market Cap.	Importance
5/24/24	Sang-Hoon Kim	Others	Chief Financial Officer	404,000	2.1053%
5/19/24	Sang-Hoon Kim	Free	Chief Financial Officer	404,000	2.1053%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GENOLUTION INC.	0.00%	+4.07%	-33.42%	-63.41%	19.63M
WUXI APPTEC CO., LTD.	-2.01%	-7.86%	+60.74%	+70.97%	70.44B
ARGENX SE	+3.84%	-11.02%	+8.59%	+57.43%	50.31B
LONZA GROUP AG	+3.35%	+1.42%	+11.85%	+40.01%	47.51B
IQVIA HOLDINGS INC.	+0.51%	+1.51%	+27.96%	+31.43%	42.91B
REVOLUTION MEDICINES, INC.	+2.70%	-3.66%	+307.41%	+547.01%	40.39B
BEONE MEDICINES AG	+0.69%	-3.44%	+9.52%	+96.59%	39.69B
CELLTRION, INC.	+0.06%	-2.02%	+11.25%	+43.27%	30.59B
WUXI BIOLOGICS (CAYMAN) INC.	-0.20%	-8.24%	+38.12%	+1.31%	26.8B
BIONTECH SE	-0.39%	-6.92%	-13.60%	-14.40%	22.36B
Average	+0.86%	-4.19%	+42.84%	+81.02%	37.1B
Weighted average by Cap.	+0.96%	-4.89%	+54.79%	+102.69%

	2024	2025
Net sales	7.14B 5.32M 4.78M 4.46M 4.04M 7.59M 506M 7.64M 53.54M 20.9M 263M 19.96M 19.53M 845M	9.4B 7.01M 6.3M 5.88M 5.33M 10M 667M 10.07M 70.56M 27.55M 346M 26.31M 25.74M 1.11B
Net income	-6.83B -5.09M -4.57M -4.27M -3.87M -7.26M -484M -7.31M -51.21M -20M -251M -19.09M -18.68M -808M	-11.64B -8.67M -7.8M -7.28M -6.6M -12.39M -826M -12.46M -87.35M -34.11M -428M -32.57M -31.86M -1.38B
Net Debt	-8.95B -6.67M -6M -5.59M -5.07M -9.52M -635M -9.58M -67.15M -26.22M -329M -25.04M -24.49M -1.06B	-3.89B -2.9M -2.6M -2.43M -2.2M -4.13M -276M -4.16M -29.15M -11.38M -143M -10.87M -10.63M -460M